Shire is to bolster its burgeoning regenerative medicine division by acquiring substantially all of the assets of Pervasis Therapeutics in a deal that is reportedly worth as much as US$200 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: PharmaDeals Ltd